Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
48.60
-1.33 (-2.65%)
Streaming Delayed Price
Updated: 2:24 PM EDT, Mar 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
↗
March 31, 2025
Via
The Motley Fool
Topics
Government
World Trade
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
↗
March 31, 2025
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.
Via
Investor's Business Daily
The Future of Healthcare: 10 Predictions For The Next Decade
March 27, 2025
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...
Via
MarketMinute
Topics
Artificial Intelligence
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
↗
February 28, 2025
Via
The Motley Fool
Market Whales and Their Recent Bets on CRSP Options
↗
February 20, 2025
Via
Benzinga
2 Beaten-Down Stocks to Buy on the Dip
↗
March 22, 2025
Via
The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
↗
March 19, 2025
Via
The Motley Fool
Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Most
↗
March 15, 2025
Via
Benzinga
Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermath
↗
March 11, 2025
On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQ:TEM), Block Inc. (NYSE:XYZ), and DraftKings Inc.<
Via
Benzinga
Topics
Artificial Intelligence
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
↗
February 28, 2025
Via
The Motley Fool
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
↗
February 24, 2025
Via
The Motley Fool
This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
↗
February 18, 2025
Via
Benzinga
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
↗
February 16, 2025
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
Via
Benzinga
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
February 14, 2025
Via
Benzinga
This Informatica Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
↗
February 14, 2025
Via
Benzinga
This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
↗
February 14, 2025
Via
Benzinga
The Ultimate Healthcare Stock to Buy With $500 Right Now
↗
February 14, 2025
Via
The Motley Fool
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
↗
February 12, 2025
Via
The Motley Fool
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
↗
February 12, 2025
Via
Benzinga
Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain.
↗
February 11, 2025
The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers.
Via
Investor's Business Daily
Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move
↗
February 10, 2025
Via
The Motley Fool
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
↗
February 02, 2025
Via
The Motley Fool
Cathie Wood's Ark Invest Bets On Biotech With CRISPR Therapeutics Investment, Exits Roblox
↗
January 31, 2025
Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.
Via
Benzinga
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
January 23, 2025
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
Via
MarketBeat
My Top 5 Stocks to Buy in Early 2025
↗
January 23, 2025
Via
The Motley Fool
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
↗
January 22, 2025
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
Via
Benzinga
3 Unstoppable Stocks to Buy in 2025
↗
January 18, 2025
Via
The Motley Fool
Cathie Wood's Ark Invest Is Betting Big On This AI Darling And No It's Not Nvidia
↗
January 18, 2025
Ark Invest made significant trades involving Tempus AI, CRISPR Therapeutics, UiPath, Roblox, Reddit, Accolade, and Ibotta. ARKG and ARKK funds bought shares, while ARKW and ARKF funds sold shares.
Via
Benzinga
Topics
Artificial Intelligence
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows
↗
January 16, 2025
Via
The Motley Fool
Vertex's Pain Drug: Big Pharma's Next Major Success?
January 16, 2025
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
